Navigation Links
ORTHOCON®, Inc. Receives 510(k) Clearance to Market HEMASORB Apply™
Date:6/1/2011

IRVINGTON, N.Y., June 1, 2011 /PRNewswire/ -- ORTHOCON®, Inc., a privately-held therapeutic device company, today announced that the Food and Drug Administration cleared HEMASORB Apply™ for clinical use and sale in the United States.

HEMASORB Apply is a proprietary, custom-designed applicator preloaded with HEMASORB® Absorbable Bone Hemostat Matrix. The product is provided ready-to-use and enables precise application of HEMASORB to stop bone bleeding during surgical procedures and in treating traumatic injuries. Currently marketed bone hemostat products require surgeons to use their fingers or surgical instruments for application. Unlike bone waxes, HEMASORB is putty-like in consistency, does not require preparation, and is now provided in a syringe-like applicator. Furthermore, HEMASORB is absorbable, biocompatible, and water resistant.

Commenting on the significance of the HEMASORB Apply clearance, John J. Pacifico, ORTHOCON's President and Chief Executive Officer, said the following: "This regulatory clearance is an important achievement for ORTHOCON. There has been very little innovation in the bone hemostat field since bone wax was first introduced in the late 1800s. We believe that the widespread adoption of flowable surgical hemostats has created new opportunities for advanced surgical products that more efficiently and effectively control bone bleeding, and we are confident that HEMASORB Apply will help secure ORTHOCON's leadership position in this therapeutic category. Both HEMASORB and HEMASORB Apply are clearly differentiated from wax-like hemostats, and they are changing the way surgeons think about surgical hemostasis."

Since its initial market introduction in 2010, HEMASORB has been approved for sale at leading hospitals throughout the United States and has been used successfully by hundreds of surgeons. ORTHOCON is confident HEMASORB Apply will provide surgeons with an innovative and cost effective tool to assist in their management of intra-operative bone bleeding, and the company fully expects HEMASORB to become the standard of care for bone hemostasis.

Control of bleeding from cut bone is a problem in many operative procedures including spine, orthopedic, craniomaxillofacial, and cardiac surgeries. Excessive bleeding during surgery may impair the surgeon's view of the operative field, may result in the need for blood transfusions, and may be associated with post-operative complications. ORTHOCON estimates that over 3.5 million patients undergoing surgeries in the United States, Europe, and Canada each year could benefit from the intra-operative use of HEMASORB.

About ORTHOCON

Founded in 2005, ORTHOCON develops, manufactures, markets, and sells implantable products that stop bone bleeding. ORTHOCON's technology platform is also being developed to improve bone healing and enable controlled, local drug delivery to the treatment site.

ORTHOCON is funded by leading international venture capital investment firms. The company occupies 8,000 square feet at its state-of-the-art facility in Irvington, New York. For more information, please visit www.orthocon.com.


'/>"/>
SOURCE ORTHOCON, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... F ast ... at the point of ... technical and medical information products and services, has launched a ClinicalKey ... information via a mobile device. Elsevier designed the mobile app to allow ... app is available in Android and iOS formats ...
(Date:2/11/2016)... DIEGO , Feb. 11, 2016 ... groundbreaking cell-isolation method that opens the door to ... until now have been impossible to isolate with ... to isolate specific tumor types in various stages ... genetic variants of these cells that are clinically ...
(Date:2/11/2016)... Conn. , Feb. 11, 2016  NanoViricides, ... that it has entered into an agreement with ... its nanoviricides® drug candidates in standard animal models ... Romanowski , Research Director. Dr. Romanowski has extensive ... discovery. --> Eric Romanowski , ...
Breaking Medicine Technology:
(Date:2/11/2016)... , ... February 11, 2016 , ... The book, “Computers ... IT services, what questions to ask your IT consultant before signing a contract and ... your computer network. , “With companies relying heavily on e-mail and technology, it’s more ...
(Date:2/11/2016)... ... ... As part of their 2015 end of year funding strategy, Colleen’s Dream ... $10,000 to University of Chicago to support ovarian cancer research being conducted by Dr. ... to support a promising young investigator from Dr. Lengyel’s lab at the University of ...
(Date:2/10/2016)... ... February 10, 2016 , ... The 9th annual meeting of ... (WMIC), will be held in New York City, NY on September 7 – ... congress will highlight and emphasize how imaging reveals a greater understanding of the ...
(Date:2/10/2016)... ... , ... Early this week, Team Iconic at J. Walter Thompson and Nestlé ... first global confectionery brand sourced from 100% sustainable cocoa. , The Nestlé Cocoa Plan ... through activities that focus on better farming, better lives and better cocoa. In order ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... care communications company offering education, research and medical media, has launched ... working in infectious diseases. , As the all-inclusive resource for infectious disease ...
Breaking Medicine News(10 mins):